Fortel Ulcer Test

Search documents
Biomerica Reports First Quarter Fiscal 2026 Financial Results
Globenewswireยท 2025-10-15 13:27
Core Insights - Biomerica, Inc. reported financial results for the first quarter ended August 31, 2025, highlighting a decrease in net sales but an improvement in gross profit due to a favorable product mix and higher-margin services [1][7][9] Financial Performance - Net sales for Q1 fiscal 2026 were $1.4 million, down from $1.8 million in Q1 fiscal 2025, attributed to reduced retail activity and international order timing, partially offset by increased sales of inFoods IBS products [7][10] - Gross margin improved to 31% from 16% year-over-year, driven by a higher-margin product mix [10] - Operating expenses decreased to $1.5 million from $1.7 million, reflecting ongoing cost discipline [8][10] - Operating loss improved to $1.1 million from $1.4 million, with a net profit of approximately $2,000 compared to a net loss of $1.3 million in the prior year [9][10] Product Developments - The inFoods IBS test received a Proprietary Laboratory Analysis (PLA) code, facilitating reimbursement claims for healthcare providers [2] - The UAE Ministry of Health approved the Fortel Ulcer Test and Fortel Kidney Test for home use, enhancing access to diagnostic tools for gastric diseases and kidney damage [3][4] - Biomerica launched the AI-backed inFoods IBS Trigger Food Navigator to support personalized dietary plans for IBS patients [5] Clinical Validation - A multicenter trial published in June 2025 demonstrated the effectiveness of the inFoods IBS test, with significant outcomes in symptom relief for IBS patients [12][14]